Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

What key factors are powering the surge in the praluent market right now?

In recent times, the Praluent market size witnessed a XX (HCAGR) growth. Its growth projection is from $XX million in 2024 to $XX million in 2025, having a compound annual growth rate (CAGR) of XX%. This expansion during the historic period is due to factors such as an increasing elderly population, heightened spending on cholesterol control treatments, growing awareness of healthcare, the requirement for more advanced hypercholesterolemia therapies, and the escalating prevalence of hypercholesterolemia and heart diseases across the globe.

How fast Is the praluent market expected to grow, and what’s its future value?

The anticipated expansion of the praluent market is projected to achieve a XX (FCAGR) over the upcoming years, escalating to a value of $XX million by 2029, paired with a compound annual growth rate (CAGR) of XX%. The surge in this predicted timeframe is a consequence of the rising incidence of cardiovascular conditions, heightened consciousness about managing hyperlipidemia, an escalated requirement for efficient treatments to reduce cholesterol, enhanced utilization of PCSK9 inhibitors, a growing penchant for individualized medicine, and heightened investments in healthcare. Key trends forecasted for this period include the creation of enhanced dosage formulations, the evolution of medicinal delivery devices, the amalgamation with digital health advancements for remote monitoring, progress in biotechnological fields, and the embracing of personalized medicine.

Get your praluent market report here!

https://www.thebusinessresearchcompany.com/report/praluent-global-market-report

What are the leading drivers of growth in the praluent market?

The increasing incidence of cardiovascular ailments is predicted to fuel the expansion of the praluent market. Cardiovascular illnesses encompass a range of disorders that affect the heart and blood vessels, including coronary artery disease, heart attacks, and strokes. The escalating occurrence of these diseases can mainly be attributed to the growing prevalence of unhealthy lifestyles, such as poor nutrition, lack of physical activity, and increased tobacco and alcohol consumption. Praluent, by lowering LDL cholesterol via PCSK9 inhibition, plays a significant role in managing cardiovascular diseases, thus decreasing the risk of heart attacks and strokes. For example, in December 2022, the Office for National Statistics, a UK government agency, reported that 3.6 million people were suffering from a cardiovascular disease (6.4%), 3.7 million from a respiratory disease (6.8%), and 6.6 million people (12.1%) were afflicted with one of these diseases in March 2021. As a result, the growing prevalence of cardiovascular diseases is a key driver for the developing praluent market.

What are the key segments defining the praluent market?

The praluent market covered in this report is segmented –

1) By Indication: Primary Hypercholesterolemia; Mixed Dyslipidemia; Established Atherosclerotic Cardiovascular Disease (ASCVD)

2) By Distribution Channel: Hospitals And Clinics; Retail Pharmacies; Specialty Pharmacies

3) By End-User: Ambulatory Care; Home Care

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20261&type=smp

Who are the key players steering the development of the praluent market?

Major companies operating in the praluent market are Sanofi S.A.; Regeneron Pharmaceuticals Inc.

What emerging trends are influencing the growth of the praluent market?

A significant trend in the praluent market is steering towards the creation of innovative solutions such as therapies that lower low-density lipoprotein cholesterol (LDL-C), with the aim to refine and improve the efficiency and accuracy of patient care. LDL-C lowering therapies are essentially medical interventions devised to decrease the levels of LDL cholesterol, often referred to as ‘bad cholesterol’, in an individual’s blood to mitigate the dangers of cardiovascular diseases like heart attacks and strokes. For example, in March 2024, Regeneron Pharmaceuticals Inc., a biotechnology firm based in the US, was granted an extension of praluent (alirocumab) injection’s approval by the U.S. Food and Drug Administration (FDA) for treatment of children diagnosed with a genetic type of high cholesterol. This extended approval encompasses its application as an adjunct to diet and other LDL-C reduction therapies for pediatric patients who are 8 years or older and afflicted with heterozygous familial hypercholesterolemia (HeFH). This strategy is designed particularly to cater to the needs of children and cut down cardiovascular risks in this demographic.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20261

Which regions are most influential in expanding the praluent market?

North America was the largest region in the praluent market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the praluent market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Similar Reports By The Business Research Company:

Cardiovascular Ultrasound Global Market Report 2025

https://thebusinessresearchcompany.com/report/cardiovascular-ultrasound-global-market-report

Angina Pectoris Drugs Global Market Report 2025

https://thebusinessresearchcompany.com/report/angina-pectoris-drugs-global-market-report

Global Cardiometabolic Diseases Global Market Report 2025

https://thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: